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ABSTRACT 
Folates in the Treatment of Colorectal Cancer 
Department of Surgery 
Institute of Clinical Sciences at Sahlgrenska Academy 
University of Gothenburg 
Helena Taflin 
Background: Colorectal cancer is one of the most common cancers in the world, and 
radical surgery with total removal of the tumour (RO-resection) is the single most 
important treatment. However, chemotherapy is recommended for patients with risk 
factors and patients with metastatic disease. 5-fluoruracil (5-FU) is the cornerstone of 
chemotherapy, used either as a single drug or in combination with other drugs. 5-FU it is 
almost always combined with the folate leucovorin (LV). The aim of this thesis was to 
examine the role of polymorphisms in genes involved in folate metabolism in relation to 
treatment and to examine the levels of various folate forms in the tumours, mucosa, and 
plasma of patients who received LV or Modufolin® which is the biological isomer of 5,10-
methylenetetrahydrofolate. 
Methods: Polymorphisms in the methylenetetrahydrofolate reductase (MTHFR), 
methionine synthase (MTR), and thymidylate synthase (TYMS) genes were analysed using 
real-time PCR and TaqMan chemistry. The various folate forms were analysed in tumours, 
mucosa, and plasma using a sensitive liquid chromatography electrospray ionization 
tandem mass spectrometry technique. 
Results: There was interdependency between polymorphisms in the MTFHR and MTR 
genes, which was associated with risk of side effects and overall survival in patients with 
stage III colorectal cancer receiving adjuvant chemotherapy. Total folate levels, all well as 
tetrahydrofolate (THF) and 5,10-methyleneTHF levels were significantly higher in 
tumours than in mucosa tissue. The individual variation in folate levels in both tumours 
and mucosa was greater than the variation found when the patients were subgrouped by 
gene polymorphisms. Only half of the patients who received 60 mg/m2 LV had higher 
levels of 5,10-methyleneTHF in tumours than patients who received 0 mg/m2 LV. Patients 
with rectal cancer had significantly lower levels of 5,10-methyleneTHF compared with 
patients with colon cancer. 5,10-methyleneTHF and THF concentrations were significantly 
higher in mucosa (p<0.003, both dosages) and tumours (p<0.015) 200 mg/m2) after 
Modufolin® administration than after LV (Isovorin®) administration. 
Conclusions: Polymorphisms in folate-associated genes can affect the risk that patients 
with colorectal cancer suffer from side effects during treatment with 5-FU-based 
chemotherapy. There is wide interindividual variation in 5,10-methyleneTHF levels in 
tumour tissue and mucosa after administration of standardised doses of LV. The doses of 
LV used in Nordic FLV-treatment may result in suboptimal levels of 5,10-methyleneTHF, 
especially in patients with rectal cancer. Modufolin® administration resulted in 
significantly higher 5,10-methyleneTHF levels than the natural l-form of LV, Isovorin®, and 
may potentially increase the efficacy of 5-FU-based chemotherapy. 
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